Juncture Wealth Strategies LLC Buys 6,302 Shares of Kenvue Inc. (NYSE:KVUE)

Juncture Wealth Strategies LLC lifted its stake in Kenvue Inc. (NYSE:KVUE) by 60.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,713 shares of the company’s stock after acquiring an additional 6,302 shares during the quarter. Juncture Wealth Strategies LLC’s holdings in Kenvue were worth $357,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Grove Bank & Trust raised its holdings in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares during the period. Geneos Wealth Management Inc. bought a new stake in Kenvue in the 4th quarter valued at $29,000. Riverview Trust Co bought a new position in Kenvue during the third quarter worth $30,000. Fortitude Family Office LLC raised its position in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of Kenvue during the 3rd quarter worth about $35,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

KVUE has been the topic of several research analyst reports. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and increased their price target for the company from $21.00 to $26.00 in a report on Monday, January 6th. Citigroup lowered their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. UBS Group lowered their price objective on Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research report on Thursday, January 16th. Finally, Royal Bank of Canada raised shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $23.08.

Kenvue Price Performance

KVUE stock opened at $20.79 on Friday. The company’s 50-day moving average price is $22.14 and its two-hundred day moving average price is $21.78. The firm has a market cap of $39.85 billion, a P/E ratio of 37.79, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same period last year, the firm posted $0.31 earnings per share. The firm’s quarterly revenue was down .4% compared to the same quarter last year. On average, analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.95%. Kenvue’s dividend payout ratio is currently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.